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A B S T R A C T
The role of renin-angiotensin system inhibitors (ACE-inhibitors) or angiotensin receptor blockers (ARB) in the renal
transplant recipients (RTRs) is incompletely defined and according to the current guidelines they should be initiated af-
ter six months post-transplantation. The aim of the present paper is to evaluate the efficiency and safety of early (within
six months post-transplantation) versus late (after six months post-transplantation) initiation of ACE-inhibitors or ARB
in RTRs. The study group compromised of 108 RTRs (50 male and 58 female) who received a kidney transplant. Beside
other prescribed antihypertensive drugs all of them took and ACE inhibitors or ARB in order to achieve blood pressure
control. For this analysis purpose, recipients were stratified into two groups according to the time of ACE inhibitors/ARB
initiation into early (within six months post-transplantation) and late (after six months after transplantation) group. For
each patient haemoglobin, serum creatinine and potassium levels were analyzed at the beginning of ACE inhibitors/ARB
introduction and at the end of the first, third, sixth and twelfth month. In the 54 (50%) of the 108 patients ACE inhibi-
tors/ARB were initiated within six months post-transplantation and in 49 (90.7%) of them within three months (in 29 pa-
tients within one month; in 13 within two months; in 7 within 3 months) post-transplantation. In additional 54 (50%)
patients ACE inhibitors/ARB were initiated, but after six months post-transplantation. There was no statistically signifi-
cant difference between the two groups related to age or gender and due to the duration of dialysis treatment before the
transplantation. Analyzing the haemoglobin, creatinine and potassium serum levels after initiation of therapy with ACE
inhibitors/ARB trough observed period we did not found any statistically significant difference in all measured parame-
ters between the two groups of patients and also within the same group of patients. Therefore, according to experience
from our Institution early initiation of ACE inhibitors or ARB appears to be safe in carefully selected recipients with rela-
tively good early graft function.
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Introduction
Despite all improvements in patients and graft sur-
vival, renal transplant recipients (RTRs) continue to dye
prematurely due to accelerated cardiovascular disease
(CVD)1. Arterial hypertension (AH) is one of the impor-
tant factors that have an impact on cardiovascular mor-
bidity and mortality in general population and also in
transplant patients. The prevalence of AH is about 60%
to 90% in RTRs2,3. With traditional risk factors of AH in
RTRs additional role has impact of an immunosuppres-
sive therapy. It has been show that calcineurin inhibitors
(CNIs) and glucocorticoids (GCs) can exert hypertensive
effect while azathioprine, mycophenolate mofetil (MMF)
and mTOR inhibitors do not interfere with blood pres-
sure. The other factors of post-transplant hypertension
are: allograft dysfunction, transplant renal artery steno-
sis, age of donor and the presence of native kidneys2,4.
The majority of RTRs develop AH within one year
post-transplantation2. The current importance of ele-
vated blood pressure is lying in the fact that it can result
in decreased allograft survival that was shown by many
809
Received for publication August 30, 2013
authors as well as by Collaborative Transplant Study5.
Also AH is associated with left ventricular hypertrophy,
with the latter being an independent risk factor for heart
failure and death in RTRs. The current recommenda-
tions include RTRs as a special population with a recom-
mended blood pressure of less that 130/80 mmHg6–8, but
poorly controlled blood pressure is common among RTRs
and according to the literature only 17–35% of RTRs
achieve the target blood pressure (<130/80 mmHg)2,9,10.
All first- and second-line antihypertensive drugs can be
used for RTRs to control blood pressure6,7,8. In most
transplant centres calcium-channel blockers (CCB) are
the most common prescribed drugs in the immediate
postrenal transplant phase because, in addition to pro-
ven antihypertensive efficacy, it minimizes calcineurin
inhibitors (CNIs)-induced systemic and renal vasocon-
striction2,4. Furthermore, beta blockers (BB) are widely
recommended and are first-line treatment in the RTRs
with coronary heart disease, hart failure and arrhyth-
mias2,11. On the other hand, the role of renin-angiotensin
system inhibitors (ACE-inhibitors) or angiotensin recep-
tor blockers (ARB) in the RTRs is incompletely defined
and according to the current guidelines they should be
initiated after six months post-transplantation6–8. There-
fore, many clinicians add these drugs to the regimen
later on, when the kidney transplant is functioning well
and the serum creatinine has stabilized. This is mainly
due to the fact that they may cause hyperkalemia and
may induce anaemia, as well as in combination with a
CNI-induced vascular disease they can induce a moder-
ate decline in glomerular filtration2,12,13. But, because of
their numerous well documented »positive« effects, these
drugs are the most common prescribed antihyperten-
sives in the general population in our country14,15.
Only 20% of RTRs take one antihypertensive drug,
while in the majority of RTRs the pharmacological treat-
ment of AH is based on combination of two or more
antihypertensives in order to achieve target blood pres-
sure. In order to achieve blood pressure control some cli-
nicians prescribe ACE inhibitors or ARB much earlier
than is currently recommended3,16.
According to these observations, the aim of the pres-
ent paper is to evaluate the efficiency and safety of early
(within six months post-transplantation) versus late (af-
ter six months post-transplantation) initiation of ACE-
-inhibitors or ARB in RTRs.
Patients and Methods
Patients
The study group compromised of 108 RTRs (50 male
and 58 female) who received a kidney transplant at our
hospital between 2001 to 2011th. Beside the other pre-
scribed antihypertensive drugs all of the patients (from
the both groups) took and ACE inhibitors or ARB due to
bad blood pressure control. The decision was made by
nephrologists. Six patients received a kidney from a liv-
ing related donor and 102 patients received a cadaveric
kidney transplant. The average age was 54.1±12.4 (ran-
ge from 23 to 72) years. Dialysis treatment before trans-
plantation lasted on average 50±50.9 (range from 1 to
254) months. At the end of the observed period, 63
(58.3%) patients had creatinine lower than 120 mmol/L,
while 45 (41.7%) had a level higher than 120 mmol/L,
For this analysis purpose, recipients were stratified
into two groups according to the time of ACE inhibitors/
ARB initiation into early (within six months post-trans-
plantation) and late (after six months after transplanta-
tion) group. All patients received triple immunosuppres-
sive therapy including a CNI/MMF/GCs and induction
with IL-2 receptor blockers (daclizumab or basiliximab).
As a maintenance therapy the most of them received
CNIs (tacrolimus or cyclosporine) and MMF, with or
without low dose of GCs. Furthermore, as late mainte-
nance therapy a mTOR inhibitors were introduced in 6
patients due to CNI-nephrotoxicity or a history of tu-
mours occurrence. Patient’s characteristics are shown
Table 1.
Method
This is retrospective observation study. For the pres-
ent study, we used the usual medical records in patients
with RTRs. For each patient haemoglobin, serum creati-
nine and potassium levels were analyzed at the begin-
ning of ACE inhibitors/ARB introduction and at the end
of the first, third, sixth and twelfth month by standard
clinical chemistry techniques. Immunosuppressive and
antihypertensive therapy was performed by nephrolo-
gists.
Blood pressure was measured with a standard mercu-
ry sphygmomanometer during regular out-patient exam-
inations. We took as the criterion for defining arterial hy-
pertension a systolic blood pressure (SP) ³140 mmHg
and a diastolic pressure (DP) ³90 mmHg or the routine
use of antihypertension therapy and as a target blood
pressure we took a SP<130 and DP<80 mmHg.
Statistical analysis
Statistical analysis of data was performed using des-
criptive statistics (mean and standard deviation). Cate-
gorical variables were tested by chi-square test. Testing
the importance of the difference of two independent
groups were performed using t-test and ANOVA. P-value
<0.05 was considered to be statistically significant. Sta-
tistical analysis was made using MedCalc statistical soft-
ware package, version 10 (MedCalc, Mariakerke, Bel-
gium).
Results
In the 54 (50%) of the 108 analyzed patients ACE in-
hibitors/ARB were initiated within six months post-
-transplantation, and in 49 (90.7%) of them within three
months (in 29 patients within one month; in 13 within
two months; in 7 within 3 months) post-transplantation.
Of them 25 (46.3%) patients were taken ACE inhibitors,
while 29 (53.7%) patients were taken ARB (p=NS). The
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most common used ACE inhibitor was lisinopril (16 pa-
tients), while the most common used ARB was telmi-
sartan (19 patients). One (1.9%) patient was treated with
one antihypertensive drug, 17 (31.5%) with two, 20
(37%) with three and 16 (29.6%) patients with more than
three antihypertensive drugs.
In additional 54 (50%) patients ACE inhibitors/ARB
were initiated, but after six months post-transplanta-
tion. Of them 27 (50%) patients were taken ACE inhibi-
tors, while 27 (50%) patients were taken ARB (p=NS).
The most common used ACE inhibitor was ramipril (11
patients) and most common used ARB was telmisartan
(17 patients). In this group, five (9.3%) patients were
treated with one antihypertensive drug, 21 (38.9%) with
two, 18 (33.3%) with three and 10 (18.5%) patients with
more than three antihypertensive drugs.
None of the analyzed patients were treated with com-
bination of ACE inhibitors and ARB.
Demographic and clinical characteristics of the ana-
lyzed 108 patients stratified by the time of ACE inhibi-
tors/ARB initiation status are shown in Table 1. There
was no statistically significant difference between the
two groups related to age or gender and due to the dura-
tion of dialysis treatment before the transplantation. On
the other hand, patients from the group two had statisti-
cally more frequently prescribed a cyclosporine as a part
of their maintenance immunosuppressive therapy.
Analyzing the haemoglobin, creatinine and potassium
serum levels after initiation of therapy with ACE inhibi-
tors/ARB trough observed period we did not find any sta-
tistically significant difference in all measured parame-
ters between the two groups of patients and also within
the same group of patients (Table 2a, 2b and 2c). Al-
though we did not find statistically significant difference,
we have noticed that at the end of the observed period 33
(61.1%) patients from the first group (ACE inhibitors/
ARB <6 months) had creatinine <120 mmol/L, while
only 26 (48.1%) patients from the second group had
creatinine <120 mmol/L.
None of the patients hadn’t side effect such as angio-
edema. In the first group, four patients had potassium
values above the reference value (>5.1 mmol/L) after the
follow-up of one month, two patients after three months,
four after six months and one patient after the follow up
of 12 months. Furthermore, analyzing the occurence of
hyperkalemia in the second group of patients we have
found that two patients had potassium values above the
reference value after the follow-up of one month, one pa-
tient after three months, three after six months and two
patients after the follow up of 12 months. None of the pa-
tients from the both groups and out the whole observed
period hadn’t potassium value of more than 5.6 mmol/L
and didn’t require treatment.
After the follow-up of 12 months we have noticed that
only 14 (25.9%) patients in the first group and 13 (24.1%)
patients in the second group achieved the target blood
pressure (<130/80 mmHg) (p=NS).
Discussion
Hypertension is a common concomitant disease in
RTRs, and in most cases requiring initiation of antihy-
pertensive therapy to achieve target blood pressure. Spe-
cific recommendations for this particular population are
lacking and data about using different classes of anti-
hypertensive are incompletely defined. Although, the
current guidelines recommended that RTRs should be
treated with any class of antihypertensive agents. Espe-
cially when urine protein excretion is significant (>1 g/d)
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TABLE 1








Total, N (%) 54 (50%) 54 (50%) NS
Male, N (%) 24 (44.4%) 26 (48.1%) NS
Female, N (%) 30 (55.6%) 28 (51.9%) NS
Duration of RRT prior
to tx (months)
49.6±45.1 48.4±49.4 NS






Glomerulonephritis 20 (37%) 22 (40.7%) NS
Pyelonephritis 6 (11.1%) 8 (14.8%) NS
Nondiabetic nephrop 9 (16.7%) 7 (13%) NS
Diabetic nephropathy 4 (7.4%) 4 (7.4%) NS
Polycystic kidney
disease
5 (9.3%) 4 (7.4%) NS
Other 10 (18.5%) 9 (16.7%) NS
Corticosteroid use 47 (87%) 50 (90.7%) NS
CNIs use
Tacrolimus 38 (70.4%) 24 (44.4%) 0.011
Sandimmun 9 (16.7%) 22 (40.7%) 0.011
MMF 49 (90.7%) 49 (90.7%) NS
m-TOR 5 (9.3%) 3 (5.6%) NS
Concomitant aspirin use 27 (50%) 27 (50%) NS
Concomitant statin use 27 (50%) 28 (51.9%) NS
BB use 35 (64.8%) 30 (55.6%) NS
CCB use 42 (77.8%) 40 (74.1%) NS
CCB and BB use 25 (46.3%) 24 (44.4%) NS
Diuretic use 18 (33.3%) 20 (37%) NS
ACE – ACE inhibitors, ARB – angiotensin receptor blockers, m –
months, y – years, nondiabetic nephrop – non-diabetic nephro-
pathy of vascular origin, BB – beta blockers, CCB – calcium
channel blockers CNIs – calcineurin inhibitors, GCs – glucocor-
ticoids, MMF – mycophenolate mofetil, NS – non-significant,
RAAS – renin-angiotensin-aldosteron inhibitors, RRT – renal
replacement therapy, tx – transplantation
ACE inhibitors or ARB are recommended as a first line
treatment. The main goal of treatment is to achieve
blood pressure control and possibly achieve the target
value6–8.
CCBs are an attractive option in any period following
transplantation and for early treatment of hypertension
after transplantation2,17,18. Their clinical usefulness was
documented by recent meta-analysis that has showed
that CCBs reduce the risk of graft loss by approximately
25% and improve graft function19. On the other hand,
other drugs, such as ACE inhibitors or ARB are not uni-
versally recommended, especially within first six months
post-transplantation. This is mainly due to several rea-
sons. For the first, the combination of ACE-inhibitors or
ARB and CNI-induced vascular disease can induce a
moderate decline in glomerular filtration rate. Secondly,
CNIs tends to raise the plasma potassium levels and this
phenomenon can be exacerbated by an ACE-inhibitors or
ARB. And thirdly they can induce anaemia in RTRs, low-
ering the haemoglobin levels by as much as 5–10% via a
mechanism that may be enhanced by CNIs2,6–8,18. In the
present study in a great proportion of patients ACE in-
hibitors or ARB were initiated within first six months
post-transplantation, mainly within first three months,
in patients with an initial graft function stabilisation.
Our observations shows that early initiation of ACE in-
hibitors or ARB did not have negative impact on graft
function, serum potassium and haemoglobin levels com-
pared with those recipients with late ACE inhibitors or
ARB initiation. Rather, after the one year of follow-up a
more recipients with early ACE inhibitors or ARB initia-
tion had creatinine <120 mmol/L, Although there was no
statistically significant difference in serum creatinine
values between the two groups of patients as well as
within the same group during the whole observed period,
a tendency of a lower creatinine values were noticed in
the patients with the early ACE inhibitors/ARB initia-
tion and thus maybe the explanation for our results at
the end of the observed period. Pointing a potential safe
early initiation of ACE inhibitors or ARB in patients with
relatively good early graft function20. Similar results
were observed by Jennings et al21 that were analyzed the
safety of ACE inhibitors or ARB use within first eight to
twelve weeks after transplantation. Consequently there
is an increasing tendency of ACE inhibitors or ARB initi-
ation prescription last decade22.
These observations are important considering the
»positive« effects of ACE inhibitors or ARB. Namely,
ARB and ACE inhibitors may prevent heart failure in pa-
tients with left ventricular dysfunction and may favour
the regression of left ventricular hypertrophy (LVH).
These effects are important due to the fact that a great
majority of patients who undergo renal transplantation
already have LVH and a certain degree of left ventricular
dysfunction because of the well known consequences of
End-Stage-renal disease and maintains dialysis2,13. Fur-
thermore, they have a protective role in atherosclerosis
development that is important because cardiovascular
diseases are the main cause of increased morbidity and
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TABLE 2a
COMPARASION OF HAEMOGLOBIN VALUES IN THE TWO












0. month 125.3±13.1 130±16.9 NS
1. month 125.3±13.1 128.9±17.4 NS
3. month 132.3±17.9 132±18.2 NS
6. month 132.2±9.5 129.5±16.3 NS
12. month 132.1±11.8 132±17.7 NS
p (ANOVA) NS NS
ACE – ACE inhibitors, ARB – angiotensin receptor blockers,
tx – transplantation, NS – non-significant
TABLE 2b
COMPARASION OF CREATININE VALUES IN THE TWO GROUPS












0. month 125.2±57.3 127.2±48.7 NS
1. month 125.4±57.3 127.2±49.7 NS
3. month 112.7±31 121.6±37.3 NS
6. month 111.6±28.7 123.2±38.8 NS
12. month 109.8±29.5 120.9±36.6 NS
p (ANOVA) NS NS
ACE – ACE inhibitors, ARB – angiotensin receptor blockers,
tx – transplantation, NS – non-significant
TABLE 2c
COMPARASION OF POTASSIUM VALUES IN THE TWO GROUPS












0. month 4.3±0.5 4.3±0.4 NS
1. month 4.6±0.5 4.4±0.5 NS
3. month 4.8±0.4 4.3±0.5 NS
6. month 5.1±5.4 4.4±0.9 NS
12. month 4.4±0.4 4.4±0.6 NS
p (ANOVA) NS NS
ACE – ACE inhibitors, ARB – angiotensin receptor blockers,
tx – transplantation, NS – non-significant
mortality in RTRs1. Namely, according to the study by
Cieciura et al23 ACE inhibitors or ARB in RTRs can pre-
vent an increase in the thickening of the intima-media
complex of the carotid artery. And additional benefits of
these drugs are their antiproteinuric effect and improve-
ment of post-transplantation eritrocytosis2,4.
In present study the most of our patients required a
combination of antihypertensive drugs and only small
proportion of them, in both groups, achieved the target
blood pressure (<130/80 mmHg) after one-year of follow
up. These results are in accordance with the previous re-
ports that showed that in majority of RTRs the pharma-
cological treatment is often based on combination of two
or more antihypertensive drugs and in most studies only
17–35% of RTRs achieved the target blood pressure val-
ues. Pointing that a more »aggressive« approach for the
management of hypertension in this population of pa-
tients is needed.
Therefore, according to experience from our Institu-
tion early initiation of ACE inhibitors or ARB appears to
be safe in carefully selected recipients with relatively
good early graft function. Recipients with a good graft
function may benefit from their early use due to their nu-
merous positive effects. The introduction of ACE inhibi-
tors or ARB as a part of antihypertensive therapy in
RTRs especially in early post-transplantation period re-
quires frequent and careful monitoring of these patients.
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UPOTREBA ANGIOTENZIN INHIBITORA I BLOKATORA ANGIOTENZINSKIH RECEPTORA
U RANOM PERIODU NAKON TRANSPLANTACIJE BUBREGA
S A @ E T A K
Prema sada{njim preporukama upotreba inhibitora angiotenzin konvertiraju}eg enzima (ACE inhibitor) ili bloka-
tora angiotenzinskih receptora (ARB) u primatelja bubre`nog transplantata nije preporu~ljiva u ranom periodu nakon
transplantacije. Cilj ovog rada je procijeniti u~inkovitost i sigurnost rane primjene (u prvih {est mjeseci nakon trans-
plantacije) u odnosu na kasnu primjenu (nakon {est mjeseci od transplantacije) ACE inhibitora ili ARB-a. Ispitivanu
skupinu ~inilo je 108 bolesnika sa bubre`nim transplantatom (50 mu{karaca nad 58 `ena) koji su u terapiji imali ACE
inhibitor ili ARB u cilju kontrole krvnog tlaka. Primatelji su bili podijeljeni u dvije skupine, prema vremenu uvo|enja
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ACE inhibitora ili ARB-a. Ranu skupinu ~inili su bolesnici kod kojih su ACE inhibitor ili ARB uveden u toku prvih 6
mjeseci nakon transplantacije, a kasnu skupinu oni kojima su navedeni lijekovi uvedeni nakon 6 mjeseci od transplan-
tacije. U svakog bolesnika analizirani su: serumske vrijednosti kreatinina, kalija i hemoglobina, na po~etku uvo|enja
terapije, te nakon jednog, tri, {est i dvanaest mjeseci. U 54 (50%) od 108 analiziranih bolesnika ACE inhibitori/ARB su
uvedeni u prvih {est mjeseci nakon transplantacije, a u najve}em broju njih u prva tri mjeseca (90,7%). U dodatnih 54
(50%) bolesnika ACE inhibitori / ARB su uvedeni nakon {est mjeseci od transplantacije. Nije bilo statisti~ki zna~ajne
razlike izme|u dviju skupina obzirom na dob, spol i trajanje dijalize prije transplantacije. Analiziraju}i vrijednosti he-
moglobina, serumskog kreatinina i kalija u navedenom vremenskom razdoblju nije bilo statisti~ki zna~ajne razlike
izme|u grupa, kao niti unutar iste grupe. Nakon 12 mjeseci pra}enja ciljne vrijednosti krvnog tlaka postiglo je u prvoj
skupini 14 (25,9%) bolesnika, a u drugoj 13 (24,1%) (p=NS). Prema na{em iskustvu mo`emo zaklju~iti da je rana
primjena ACE inhibitora ili ARB nakon transplantacije bubrega sigurna.
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